Top Markets
#1 Ontology Gas Ontology Gas +26.18%
#2 Verus Coin Verus Coin +22.50%
#3 EXOD EXOD +22.08%
#4 Status Status +19.02%
#5 ETHGas ETHGas +17.85%
#6 Bitway Bitway +15.81%
#7 Geodnet Geodnet +14.32%
#8 Curve DAO Curve DAO +11.70%
#9 Derive Derive +11.25%
#10 The Black Bull The Black Bull +11.14%
Coin of the day
Ontology Gas Ontology Gas
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Carna Biosciences, Inc. Carna Biosciences, Inc.

Carna Biosciences, Inc.

4572
Classificação em ações #25406
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a... Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly within the Japanese market. In addition to its drug discovery efforts, Carna Biosciences offers an array of specialized research tools. These comprise diverse kinase proteins, their corresponding substrates, comprehensive kinase protein assay kits, stable cell lines, and biotinylated kinases, which are instrumental in investigating kinase-molecule interactions. The company also delivers a wide spectrum of scientific services. These services span from in-depth profiling and various cell-based kinase assays, including NanoBRET TE and ClariCELL intracellular assays, to protein detection and interaction analysis, live-cell kinase assays, crystallization, and weak affinity chromatography. Furthermore, they provide tyrosine kinase cell-based assay services and custom synthesis of ultra-pure proteins specifically for crystallography. Its therapeutic pipeline highlights several key investigational compounds. AS-0141, an orally administered small molecule designed to inhibit CDC7 kinase, is currently undergoing preclinical studies for cancer treatment. Another small molecule, AS-0871, is advancing through Phase 1 clinical trials for inflammatory and immune disorders. Moreover, AS-1763, an orally bioavailable, non-covalent inhibitor, is in preclinical assessment for chronic lymphocytic leukemia and other B-cell malignancies. Strategic collaborations have been established with leading pharmaceutical organizations, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals.
Preço da ação
$2.62
Valor de mercado
$50.19M
Variação (1 dia)
-1.47%
Variação (1 ano)
77.21%
País
JP
Negociar Carna Biosciences, Inc. (4572)

Categoria

Healthcare
Histórico de preços das ações de Carna Biosciences, Inc. (4572)
Preço de fecho mais alto: $2.33 em 2026-08-01

Preço de fecho mais baixo: $9.84 em 2008-03-01
Histórico de preços das ações da Carna Biosciences, Inc. de 2008 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) -2.66%
2025 11.27%
2024 -56.72%
2023 0.20%
2022 -48.88%
2021 -27.88%
2020 -39.08%
2019 101.34%
2018 -2.61%
2017 -38.05%
2016 -28.59%
2015 261.37%
2014 -16.25%
2013 159.13%
2012 -15.00%
2011 -31.55%
2010 -18.51%
2009 -1.93%
2008 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $539.14 35.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 56.21%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $118.42 -18.43%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $761.87 8.65%
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $130.43 397.46%
US